(A) Copy number of UT2 in solid tumors and hematological cancer cell lines (Broad-Novartis Cancer Cell Line Encyclopedia [n = 338; left panel] and Oncomine database corresponds to GSE20306 data [n = 449] derived from ref. 46 [right panel]). Numbers in parentheses are n values. (B) Copy number of UT2 in primary MM patients were assessed using human genome CGH microarray data obtained from the Oncomine database. Left panel corresponds to GSE26849 data (MGUS [n = 2], MM [n = 249], and plasma cell leukemia [n = 10]) from ref. 56, and right panel corresponds to GSE15695 data (normal donor [n = 84] and MM [n = 84]) from ref. 55. (C) UT2 expression from primary MM patients were assessed using human genome CGH microarray data obtained from the Oncomine database. C panel corresponds to data from refs. 55–59 (GSE2658 data [n = 414], GSE4452 data [n = 65], GSE15695 data [n = 247], GSE26760 data [MGUS (n = 2), MM (n = 299), and plasma cell leukemia (n = 3)], and GSE29023 data [n = 115]). (D) Survival curve relative to UT2 expression (high expression [n = 160] and low expression [n = 382]) in individuals affected by myeloma and based on GSE2658 (58) (log-rank test). (E) Quantitative PCR (qPCR) analyses of UT2 expression in different human control cancer cells and myeloma cells (n = 3 experiments; two-tailed, unpaired t test; **P < 0.01). (F and G) qPCR and Western blots analyses of UT2 expression from primary MM patients. CD138⁺ myeloma cells and CD138^– BM cells were isolated from primary MM patient BM cells, and qPCR analysis (F) (normal donor BM cells [left panel] and CD138^– BM fractions [right panel]) and Western blot analysis (G) were performed, respectively. See also Supplemental Figure 3B. Data are shown as mean ± SEM (n = 5–6; two-tailed, unpaired t test; **P < 0.01).